

*National Imaging Associates, Inc.	
Clinical guidelines: SMALL CELL LUNG CANCER	Original Date: March 2011
Radiation Oncology	Last Revised Date: May 2023
Guideline Number: NIA_CG_123	Implementation Date: January 2024

GENERAL INFORMATION

- *It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.*
- *Where a specific clinical indication is not directly addressed in this guideline, medical necessity determination will be made based on widely accepted standard of care criteria. These criteria are supported by evidence-based or peer-reviewed sources such as medical literature, societal guidelines and state/national recommendations.*

INDICATIONS FOR RADIATION THERAPY

Limited-Stage SCLC (T1-2, N1-N3 M0)¹

- 2D or 3D Conformal Radiation Therapy (3DCRT)
- Two randomized phase III trials did not demonstrate superiority of 66 Gy in 6.5 weeks/2 Gy daily (the European CONVERT trial) or 70 G in 7 weeks/2 Gy daily (CALGB 30610/RTOG 0538) over 45 Gy in 3 weeks/1.5 Gy BID, but overall survival and toxicity were similar²⁻⁴

Dosage Guidelines:

- Up to 30 fractions is medically necessary

Extensive-Stage SCLC (T any, N any, M1a/b)¹

- Consolidative thoracic RT is beneficial for selected patients with ES-SCLC with complete response or good response to systemic therapy, especially with residual thoracic disease and low-bulk extrathoracic metastatic disease
- The Dutch CREST randomized trial of modest-dose thoracic RT (30 Gy in 10 fractions) in patients with ES-SCLC that responded to systemic therapy demonstrated significantly improved 2-year overall survival and 6-month progression-free survival. Benefit of

consolidative thoracic RT is limited to the majority of patients who had residual thoracic disease after systemic therapy^{5,6}

- 2D or 3D Conformal Radiation Therapy (3DCRT) Radiation therapy to treat symptomatic sites or treatment of cord compression

Dosage Guidelines:

- 30 Gy in 10 daily fractions up to definitive dosing regimens in patients with a longer life expectancy.
- Up to 30 fractions is medically necessary

Prophylactic Cranial Irradiation (PCI)

- The benefit of PCI is unclear in patients who have undergone definitive therapy for very early LS-SCLC, i.e., pathologic stage I–IIA (T1–2, N0, M0)⁷
- However, PCI may have a benefit in patients who are found to have pathologic stage IIB or III SCLC after complete resection^{7,8}
- Routine PCI is not indicated for Extensive stage patients.
- PCI is not recommended in patients with poor performance status or impaired neurocognitive function⁹
- Brain MRI surveillance should be performed in patients not receiving PCI⁷

Hippocampal Sparing Intensity Modulated Radiation Therapy for PCI^{1,10,11} **(Will be reviewed on a case-by-case basis)**

- A phase III randomized trial of HA-WBRT versus conventional WBRT demonstrated improved cognitive preservation and patient-reported outcomes with HA-WBRT in patients with brain metastases from mixed histologies¹⁰
- For patients with a better prognosis (e.g., ≥4 months), hippocampal-sparing WBRT using IMRT plus memantine is preferred because it produces less cognitive function failure than conventional WBRT plus memantine¹⁰
- Hippocampal sparing whole brain IMRT (plus memantine) is considered medically necessary for individuals with all of the following:
 - Good performance status: ECOG rating is less than 3
 - Who have a prognosis of at least 4 months
 - No metastases within 5mm of the hippocampi
 - Have not had prior WBRT or external beam radiation to the brain
 - Do not have leptomeningeal disease

2D or 3D Conformal Radiation Therapy (3DCRT) is indicated for in patients with poor performance status or impaired neurocognitive function.

Dosage Guidelines

- The preferred dose for PCI to the whole brain is 25 Gy in 10 daily fractions.

TREATMENT OPTIONS (to be reviewed on a case-by-case basis)

Intensity Modulated Radiation Therapy (IMRT)

IMRT is not indicated as a standard treatment option and should not be used routinely for the delivery of radiation therapy for small cell lung cancer. IMRT may be appropriate for limited circumstances in which radiation therapy is indicated and 3D conformal radiation therapy (3D-CRT) techniques cannot adequately deliver the radiation prescription without exceeding normal tissue radiation tolerance, the delivery is anticipated to contribute to potential late toxicity or tumor volume dose heterogeneity is such that unacceptable hot or cold spots are created. If IMRT is utilized, techniques to account for respiratory motion should be performed.

Clinical rationale and documentation for performing IMRT rather than 2D or 3D-CRT treatment planning and delivery will need to:

- Demonstrate how 3D-CRT isodose planning cannot produce a satisfactory treatment plan (as stated above) via the use of a patient-specific dose volume histograms and isodose plans.
- Provide tissue constraints for both the target and affected critical structures.

Proton Beam Radiation Therapy

Proton beam is not an approved treatment option for small cell lung cancer. There are limited clinical studies comparing proton beam therapy to 3-D conformal radiation. Overall, studies have not shown clinical outcomes to be superior to conventional radiation therapy.

Stereotactic Body Radiation Therapy (SBRT)^{1, 12-20}

SBRT is approvable for clinical stage I to IIA (T1-2,N0) Small Cell Lung Cancer who are medically inoperable or refuse surgery.

THE FOLLOWING APPLIES TO CMS (MEDICARE) MEMBERS ONLY:

For Proton Beam Radiation Therapy refer to Local Coverage Determination (LCD), if applicable.

BACKGROUND

The two major types of lung cancer are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC differs significantly from NSCLC in that most patients with SCLC present with subclinical metastatic disease. Patients with SCLC are divided into those with limited-versus extensive-stage disease.²¹ Although limited-stage disease is confined to the ipsilateral hemithorax, a third of these patients have subclinical systemic disease. Extensive-stage disease is defined as disease extending beyond the ipsilateral hemithorax, including positive pleural/pericardial effusion or distant metastases.²¹ Systemic chemotherapy is an essential

component of appropriate treatment for all SCLC patients, even those with limited-stage disease.

This guideline outlines methods suitable for the delivery of radiation therapy to treat SCLC. Radiation therapy may be delivered using conventional, accelerated fractionation, hyperfractionated regimens and prophylactic cranial irradiation. Three-dimensional conformal radiation therapy (3D-CRT) is the preferred technique. If image-guided radiation therapy is utilized, techniques to account for respiratory motion should be performed. The goal of this guideline is to guide diagnosis and treatment to the most efficient, comparatively effective, diagnostic and treatment pathway.

SCLC is highly sensitive to initial chemotherapy and radiation therapy; however, a cure is difficult to achieve because SCLC generally has a rapid doubling time, a high growth fraction, and early development of widespread metastases.

The treatment goal in patients with limited-stage disease is to achieve a cure with chemotherapy combined with thoracic radiation therapy. In patients with extensive-stage disease, this combined modality treatment does not improve survival compared with chemotherapy alone, but radiation therapy plays a role in palliation of symptoms. All patients with SCLC require systemic chemotherapy and where radiation therapy is utilized, it should be delivered concurrently with chemotherapy.²¹ Patients with both limited- and extensive-stage disease may benefit from prophylactic cranial irradiation (PCI), decreasing the incidence of central nervous system metastases and prolonging survival. Two-dimensional, post lateral fields should be used in PCI treatment.

REFERENCES

1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Small Cell Lung Cancer Version 2.2023. National Comprehensive Cancer Network (NCCN). Updated October 25, 2022. Accessed December 8, 2022. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
2. Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. *Lancet Oncol*. Aug 2017;18(8):1116-1125. doi:10.1016/s1470-2045(17)30318-2
3. Bogart JA, Wang XF, Masters GA, et al. Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538. Wolters Kluwer Health; 2021.
4. Ganti AK, Dueck AC, Fruth B, et al. Comparison of quality of life in patients randomized to high-dose once daily (QD) thoracic radiotherapy (TRT) with standard twice daily (BID) TRT in limited stage small cell lung cancer (LS-SCLC) on CALGB 30610 (Alliance, Sub-study CALGB 70702). American Society of Clinical Oncology; 2022.
5. Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. *Lancet*. Jan 3 2015;385(9962):36-42. doi:10.1016/s0140-6736(14)61085-0
6. Slotman BJ, van Tinteren H, Praag JO, et al. Radiotherapy for extensive stage small-cell lung cancer - Authors' reply. *Lancet*. Apr 4 2015;385(9975):1292-3. doi:10.1016/s0140-6736(15)60679-1
7. Yang Y, Zhang D, Zhou X, et al. Prophylactic cranial irradiation in resected small cell lung cancer: A systematic review with meta-analysis. *J Cancer*. 2018;9(2):433-439. doi:10.7150/jca.21465
8. Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. *N Engl J Med*. Aug 12 1999;341(7):476-84. doi:10.1056/nejm199908123410703
9. Le Péchoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. *Lancet Oncol*. May 2009;10(5):467-74. doi:10.1016/s1470-2045(09)70101-9
10. Brown PD, Gondi V, Pugh S, et al. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. *J Clin Oncol*. Apr 1 2020;38(10):1019-1029. doi:10.1200/jco.19.02767
11. Rodríguez de Dios N, Couñago F, López JL, et al. Treatment Design and Rationale for a Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for SCLC: PREMIER Trial on Behalf of the Oncologic Group for the Study of Lung Cancer/Spanish Radiation Oncology Group-Radiation Oncology Clinical Research Group. *Clin Lung Cancer*. Sep 2018;19(5):e693-e697. doi:10.1016/j.clc.2018.05.003

12. Shioyama Y, Onishi H, Takayama K, et al. Clinical Outcomes of Stereotactic Body Radiotherapy for Patients With Stage I Small-Cell Lung Cancer: Analysis of a Subset of the Japanese Radiological Society Multi-Institutional SBRT Study Group Database. *Technol Cancer Res Treat*. Jan 1 2018;17:1533033818783904. doi:10.1177/1533033818783904
13. Verma V, Simone CB, 2nd, Allen PK, et al. Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer. *Int J Radiat Oncol Biol Phys*. Feb 1 2017;97(2):362-371. doi:10.1016/j.ijrobp.2016.10.041
14. Videtic GM, Stephans KL, Woody NM, et al. Stereotactic body radiation therapy-based treatment model for stage I medically inoperable small cell lung cancer. *Pract Radiat Oncol*. Oct-Dec 2013;3(4):301-6. doi:10.1016/j.prro.2012.10.003
15. Alongi F, Arcangeli S, De Bari B, et al. Stage-I small cell lung cancer: A new potential option for stereotactic ablative radiation therapy? A review of literature. *Crit Rev Oncol Hematol*. Apr 2017;112:67-71. doi:10.1016/j.critrevonc.2017.02.010
16. Rathod S, Koul R, Bashir B, Chowdhury A, Dubey A. Role of Stereotactic Body Radiation Therapy in Early Stage Small Cell Lung Cancer in the Era of Lung Cancer Screening: A Systematic Review. *Am J Clin Oncol*. Feb 2019;42(2):123-130. doi:10.1097/coc.0000000000000489
17. Shioyama Y, Nakamura K, Sasaki T, et al. Clinical results of stereotactic body radiotherapy for Stage I small-cell lung cancer: a single institutional experience. *J Radiat Res*. Jan 2013;54(1):108-12. doi:10.1093/jrr/rrs075
18. Li C, Xiong Y, Zhou Z, et al. Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer: a single-center prospective phase II study. *Med Oncol*. Dec 2014;31(12):369. doi:10.1007/s12032-014-0369-x
19. Verma V, Simone CB, 2nd, Allen PK, Lin SH. Outcomes of Stereotactic Body Radiotherapy for T1-T2N0 Small Cell Carcinoma According to Addition of Chemotherapy and Prophylactic Cranial Irradiation: A Multicenter Analysis. *Clin Lung Cancer*. Nov 2017;18(6):675-681.e1. doi:10.1016/j.clcc.2017.03.009
20. American Society for Radiation Oncology. Astro Model Policies: Stereotactic Body Radiation Therapy. American Society for Radiation Oncology (ASTRO). Updated June 2020. Accessed December 8, 2022. <https://www.astro.org/ASTRO/media/ASTRO/Daily%20Practice/PDFs/ASTROSBRTModelPolicy.pdf>
21. Kong FM, Lally BE, Chang JY, et al. ACR Appropriateness Criteria® radiation therapy for small-cell lung cancer. *Am J Clin Oncol*. Apr 2013;36(2):206-13. doi:10.1097/COC.0b013e31827e5523

POLICY HISTORY

Date	Summary
May 2023	<ul style="list-style-type: none"> • Added to Limited Stage SCLC: Two randomized phase III trials did not demonstrate superiority of 66 Gy in 6.5 weeks/2 Gy daily (the European CONVERT trial) or 70 Gy in 7 weeks/2 Gy daily (CALGB 30610/RTOG 0538) over 45 Gy in 3 weeks/1.5 Gy BID, but overall survival and toxicity were similar • Added to Extensive Stage SCLC: <ul style="list-style-type: none"> ○ Consolidative thoracic RT is beneficial for selected patients with ES-SCLC with complete response or good response to systemic therapy, especially with residual thoracic disease and low-bulk extrathoracic metastatic disease. ○ The Dutch CREST randomized trial of modest-dose thoracic RT (30 Gy in 10 fractions) in patients with ES-SCLC that responded to systemic therapy demonstrated significantly improved 2-year overall survival and 6-month progression-free survival. Benefit of consolidative thoracic RT is limited to the majority of patients who had residual thoracic disease after systemic therapy (17, 18). ○ Clarified/updated Dosage Guidelines under Extensive Stage SCLC • Added to PCI <ul style="list-style-type: none"> ○ The benefit of PCI is unclear in patients who have undergone definitive therapy for very early LS-SCLC, i.e., pathologic stage I–IIA (T1–2, N0, M0) ○ However, PCI may have a benefit in patients who are found to have pathologic stage IIB or III SCLC after complete resection ○ Routine PCI is not indicated for Extensive stage patients. ○ PCI is not recommended in patients with poor performance status or impaired neurocognitive function ○ Brain MRI surveillance should be performed in patients not receiving PCI • Moved Hippocampal sparing WBRT up under PCI • Clarified/updated Hippocampal sparing WBRT <ul style="list-style-type: none"> ○ A phase III randomized trial of HA-WBRT versus conventional WBRT demonstrated improved cognitive preservation and patient-reported outcomes with HA-WBRT in patients with brain metastases from mixed histologies ○ For patients with a better prognosis (e.g., ≥4 months), hippocampal-sparing WBRT using IMRT plus memantine is

	<p>preferred because it produces less cognitive function failure than conventional WBRT plus memantine</p> <ul style="list-style-type: none"> ○ Hippocampal sparing whole brain IMRT (plus memantine) is considered medically necessary for individuals with all of the following: (added “required physician review”) <ul style="list-style-type: none"> ▪ Good performance status: ECOG rating is less than 3 ▪ Who have a prognosis of at least 4 months ▪ No metastases within 5mm of the hippocampi ▪ Have not had prior WBRT or external beam radiation to the brain ▪ Do not have leptomeningeal disease ○ 2D or 3D Conformal Radiation Therapy (3DCRT) is indicated for in patients with poor performance status or impaired neurocognitive function. ● Deleted Additional Resources ● Changed “Treatment options requiring physician review” to Treatment Options (will be reviewed on a case-by-case basis)
January 2022	<ul style="list-style-type: none"> ● Added Hippocampal Sparing Intensity Modulated Radiation Therapy for PCI, including dosage guidelines ● Updated SBRT as “approvable for clinical stage I to IIA (T1-2,N0) Small Cell Lung Cancer who are medically inoperable or refuse surgery” ● Deleted “Stereotactic Body Radiation Therapy (SBRT) is not considered a standard form of treatment for SCL cancer. SBRT may be considered medically necessary to treat a previously irradiated field A request for SBRT will require a peer review to make a medical necessity determination.”



Reviewed / Approved by NIA Clinical Guideline Committee

Disclaimer: *National Imaging Associates, Inc. (NIA) authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Evolent Health LLC subsidiaries including, but not limited to, National Imaging Associates (“NIA”). The policies constitute only the reimbursement and coverage guidelines of NIA. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. NIA reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.*